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OBJECTIVES This study was performed to assess the prognostic implications of myocardial contractile
reserve (MCR) in patients with coronary artery disease (CAD) and left ventricular (LV)
dysfunction.
BACKGROUND MCR during dobutamine stress echocardiography (DSE) identifies viable myocardium that
may improve in function after revascularization. Whether revascularization influences
prognosis of patients with MCR has not been determined.
METHODS We performed DSE in 80 patients with CAD and LV dysfunction (ejection fraction #40%).
Viable myocardium was defined in dysfunctional myocardial segments as enhanced thicken-
ing and contraction during low-dose dobutamine (5 to 10 mcg/kg/min). Serial prospective
follow-up was obtained in all patients (mean follow-up 2.2 6 1.1 years).
RESULTS Among 52 patients treated medically, there were 20 cardiac deaths. By multivariate analysis,
the number of dysfunctional segments demonstrating MCR was the strongest predictor of
survival (p , 0.03). Patients with MCR had better initial survival during medical therapy
than did those without MCR, but this survival advantage was not maintained beyond three
years. In contrast, survival was excellent in patients with MCR who underwent myocardial
revascularization. Among 58 patients with MCR in $5 myocardial segments, survival at three
years was 93 6 6% in the 24 patients who were revascularized but only 49 6 15% in the 34
treated medically (p , 0.02).
CONCLUSIONS Myocardial contractile reserve is a significant predictor of survival in patients with CAD and
LV dysfunction undergoing medical therapy. Although patients with MCR have an initial
survival advantage, this advantage is lost over the course of three years. In contrast, survival
in patients with significant MCR is enhanced by revascularization. (J Am Coll Cardiol 1999;
34:730–8) © 1999 by the American College of Cardiology
In patients with coronary artery disease (CAD), left ven-
tricular (LV) systolic function is among the most important
determinants of long-term outcome. It is well established
that patients with severe LV dysfunction have a poor
prognosis (1–5). However, LV dysfunction is not always an
irreversible process, because LV function may improve
substantially in a subset of patients after myocardial revas-
cularization (6–11). Data obtained using positron emission
tomography (PET) suggest that this improvement in LV
function may translate into improved functional status and
long-term survival (12–14). Hence, the identification of
patients with dysfunctional myocardium that is viable and
has the potential for recovery of function has important
implications regarding the selection of patients for myocar-
dial revascularization.
Dobutamine stress echocardiography (DSE) is an inex-
pensive, readily available and accurate method of identifying
contractile reserve in myocardial regions with resting wall-
motion abnormalities (15–35). The demonstration of con-
tractile reserve by this technique has been shown to predict
functional improvement after revascularization, indicating
that DSE may be used to identify dysfunctional but viable
myocardium (17–20,22,24 –28,30 –32,34). However,
whether the presence of contractile reserve also provides
prognostic information in patients with LV dysfunction has
not been determined. In the current study, we assessed the
prognostic implications of contractile reserve as a marker of
myocardial viability in patients with CAD and impaired LV
function.
METHODS
Patient selection. We studied 80 patients with CAD and
chronic LV dysfunction (ejection fraction #40%), who
underwent DSE at Northwestern Memorial Hospital or the
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Veterans Administration Lakeside Medical Center in Chi-
cago, Illinois between January 1992 and July 1994. This
represents a consecutive series of patients with LV dysfunc-
tion undergoing DSE at our institutions during this time
period. Coronary artery disease was documented by previous
myocardial infarction, coronary arteriography, or both.
There were 64 men and 16 women, ranging in age from 28
to 85 years (mean 64 6 12 years). Sixty-eight of the 80
patients had a history or electrocardiographic (ECG) evi-
dence of previous myocardial infarction. The LV ejection
fraction ranged from 12% to 40% (mean 27 6 7%). All
patients gave informed written consent for the DSE study.
Dobutamine stress echocardiography. Transthoracic
echocardiographic images were obtained with the patient in
the left lateral decubitus position using commercially avail-
able ultrasound equipment (Sonos 1000 or Sonos 1500 with
a 2.0–3.5-MHz transducer, Hewlett-Packard, Andover,
Massachusetts). Four standard echocardiographic views
were obtained with each acquisition: parasternal long axis,
parasternal short axis, apical 4-chamber and apical
2-chamber views. The left ventricle was divided into 16
segments as recommended by the American Society of
Echocardiography (36), and a score was assigned to each
segment at baseline, low dose and peak dose of dobutamine
infusion. Each segment was scored as follows: 1 5 normal;
2 5 mild to moderate hypokinesis (reduced wall thickening
and excursion); 3 5 severe hypokinesis (markedly reduced
wall thickening and excursion); 4 5 akinesis (no wall
thickening or excursion); 5 5 dyskinesis (paradoxical wall
motion away from the center of the left ventricle during
systole). All echocardiograms were interpreted by an expe-
rienced echocardiographer who was unaware of the patient’s
treatment and outcome.
Dobutamine was administered intravenously beginning
at a dose of 2.5 to 5 mg/kg/min and increased by 5 to
10 mg/kg/min every 3 min up to a maximum of
50 mg/kg/min, or until a study end point was achieved. The
end points for termination of the dobutamine infusion
included development of new segmental wall-motion ab-
normalities, attainment of 85% of age-predicted maximum
heart rate or the development of significant adverse effects
related to the dobutamine infusion. Atropine was adminis-
tered intravenously in 0.25-mg increments every 3 min up
to a maximum of 2.0 mg if a study end point was not
achieved at the maximum dobutamine dose. Cardiac
rhythm was monitored throughout the dobutamine infusion
protocol, and 12-lead ECGs and blood pressure measure-
ments were obtained at baseline, at each stage of the
infusion protocol and during the recovery phase.
Echocardiographic images were acquired at baseline, with
each increment of dobutamine infusion (after 2 min of
infusion) and during the recovery phase. A normal response
to dobutamine was defined as normal wall motion at rest
with progressive increase in wall thickening and excursion
during dobutamine infusion. The scoring system for abnor-
mal wall-motion responses to dobutamine was the same as
that used to assess regional wall motion at rest. Contractile
reserve, indicating myocardial viability in a segment with a
baseline wall-motion abnormality, was defined as an im-
provement in wall motion with a decrease in wall-motion
score of $1 grade during dobutamine infusion. Myocardial
ischemia was defined as a deterioration in segmental func-
tion during dobutamine with an increase in wall-motion
score of $1 grade. Using these definitions, a myocardial
segment with baseline dysfunction could demonstrate both
viability at low doses of dobutamine and ischemia with the
increased oxygen demands induced by higher doses of
dobutamine (biphasic response) (22,37).
Echocardiographic LV ejection fractions were deter-
mined at baseline, low dose and peak dose of dobutamine.
The images were digitized using a commercially available
software package (Tomtec Imaging Systems, Boulder, Col-
orado). Definition of the LV endocardial surface was
performed by an experienced echocardiographer at end-
diastole and end-systole for the apical 2-chamber and apical
4-chamber views using the Tomtec Left Ventricular Func-
tion Analysis Program (Tomtec Imaging Systems, Boulder,
Colorado). Left ventricular volumes were calculated by the
modified Simpson biplane method using the apical
2-chamber and apical 4-chamber views as previously de-
scribed (38). Ejection fraction was calculated as 100% 3
(end diastolic volume 2 end systolic volume)/end diastolic
volume.
Global systolic function was assessed further by deriving
a regional wall-motion score for each patient, which was
calculated as the average of the scores of all 16 segments
(16,19,36). The regional wall-motion score was computed
at rest, during low-dose dobutamine and at the peak dose of
dobutamine.
Follow-up evaluation. Serial prospective follow-up was
obtained in all patients. After the DSE study, 52 patients
were treated medically and 28 patients underwent myocar-
dial revascularization by percutaneous transluminal angio-
plasty (7 patients), coronary artery bypass surgery (20
patients) or both (1 patient). The decision for myocardial
revascularization was at the discretion of the referring
cardiologist.
A computerized database consisting of demographic,
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clinical, angiographic and echocardiographic data was es-
tablished for the study population. Prospective follow-up
was serially obtained by means of a physician-directed
telephone interview using a standardized questionnaire. If
the patient died after the DSE study, the closest surviving
relative and the patient’s physician were interviewed to
determine the cause of death. Autopsy records were re-
viewed when available. All patients or relatives were inter-
viewed at least twice during the follow-up period (except for
those who were dead at the initial contact).
The primary end point of the study was cardiac mortality
due to sudden cardiac death, fatal myocardial infarction or
progressive congestive heart failure. Nonfatal myocardial
infarction was evaluated as a secondary event. In addition,
an assessment of New York Heart Association (NYHA)
functional class and Canadian Cardiovascular Society angi-
nal class was made before the DSE study and with each
subsequent interview. In patients who died of a cardiac
cause during the follow-up period, a NYHA functional class
IV was substituted for the missing data points. The NYHA
functional class before DSE was substituted for the missing
data points for patients who died of a noncardiac cause
during follow-up. Two patients initially treated medically
who underwent revascularization greater than one year after
DSE were considered medically treated and censored at the
time of revascularization.
Statistical analysis. Continuous data are expressed as the
mean 6 SD. The effect of clinical, DSE results and
revascularization time to cardiac death was initially assessed
using univariate Cox regression analysis (39). Variables
included in this analysis were age, gender, diabetes, history
of hypertension, smoking history, hyperlipidemia, history of
myocardial infarction, previous revascularization, number of
stenotic coronary arteries, NYHA functional class, medica-
tion use, heart rate, blood pressure, dobutamine dose,
number of dysfunctional myocardial segments with contrac-
tile reserve, number of myocardial segments with ischemic
responses, ejection fraction and the regional wall-motion
score. Variables with a significance level of p , 0.2 in the
univariate analysis were considered for inclusion in a mul-
tivariate Cox regression model, and variables with a signif-
icance level of p , 0.05 were retained in the final model.
For purposes of constructing survival curves, patient
subgroups were created using cutoff values of the number of
segments with contractile reserve that optimized positive
and negative predictive values. Differences in discrete vari-
ables among groups were assessed by chi-square analysis and
in continuous variables by analysis of variance (ANOVA).
For variables determined to be significant (p , 0.05) by
ANOVA, comparisons between groups were made using
the Bonferroni method of adjustment for multiple compar-
isons, where applicable. Life table analysis with the product-
limit method of the Kaplan-Meier estimate was used to
estimate rates of freedom from cardiac death (40); compar-
isons of survival between groups were made using the
Cox-Mantel statistic (41).
RESULTS
Patient characteristics. All patients successfully completed
the DSE protocol. The peak dobutamine dose achieved was
20.3 6 11.8 mg/kg/min. Four patients received atropine
(mean dose 1.1 6 0.6 mg) to achieve a study end point. No
patient developed significant adverse effects requiring pre-
mature termination of the dobutamine infusion protocol.
All patients manifested LV dysfunction, with multiple
segmental wall-motion abnormalities under basal conditions
(mean 15.6 6 1.1, range 10 to 16). During the dobutamine
infusion, 71 patients (89%) demonstrated contractile reserve
consistent with myocardial viability in at least one myocar-
dial segment with abnormal baseline wall motion, 62
patients (78%) demonstrated contractile reserve in $3
myocardial segments and 58 patients (73%) demonstrated
contractile reserve in $5 myocardial segments. Fifty-nine
patients (74%) developed new reversible wall-motion abnor-
malities consistent with an ischemic response during dobut-
amine infusion.
Clinical course in medically treated patients. For the 52
patients receiving medical management, the mean duration
of follow-up after DSE was 2.2 6 1.0 years (range 0.3 to 3.8
years). During that time, there were a total of 20 cardiac
deaths (38%), including 10 sudden deaths, 3 fatal myocar-
dial infarctions and 7 deaths from chronic heart failure. The
mean interval between the DSE study and cardiac death was
1.2 6 1.0 years (range 0.03 to 2.8 years). Noncardiac death
occurred in four patients.
Univariate predictors of survival are shown in Table 1.
Variables that were significantly associated with survival
included the number of dysfunctional myocardial segments
manifesting contractile reserve with low-dose dobutamine
with or without ischemic responses (monophasic or biphasic
responses) at higher dobutamine doses (p 5 0.011), the
number of myocardial segments with an ischemic response
with dobutamine (p 5 0.015), the number of dysfunctional
segments with contractile reserve without ischemia
(monophasic responses) (p 5 0.05), the LV ejection fraction
during low-dose (p , 0.04) and high-dose (p , 0.05)
dobutamine and NYHA functional class (p , 0.03). The
anatomic locations of segments with contractile reserve or
ischemic responses were not related to survival. The number
of segments with contractile reserve with low-dose dobut-
amine that had ischemic responses at higher dobutamine
doses (biphasic responses) was not a significant predictor of
mortality, nor was the regional wall-motion score at baseline
or during DSE. Age was of borderline significance, and
using angiotensin-converting enzyme (ACE) inhibitors and
beta-blockers was not significantly associated with survival.
In the multivariate Cox regression analysis, the number of
dysfunctional segments with contractile reserve during do-
butamine (p , 0.03) and NYHA functional class (p , 0.05)
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were the only significant independent predictors of freedom
from cardiac death. In contrast, the number of myocardial
segments demonstrating inducible ischemia with deteriora-
tion in wall motion during dobutamine and ejection fraction
with dobutamine were not independent predictors of sur-
vival.
On the basis of the results of the Cox regression model,
patients were put into subgroups on the basis of the number
of dysfunctional segments manifesting contractile reserve.
Among the 52 patients treated medically, 34 manifested
contractile reserve in $5 myocardial segments and 18 had
contractile reserve in ,5 segments. These two patient
groups did not differ in terms of age, gender, coronary
anatomy, prior revascularization, previous myocardial infarc-
tion, severity of symptoms or baseline ejection fraction and
regional wall-motion score (Table 2). The groups also did
not differ with respect to therapy with ACE inhibitors,
beta-blockers, calcium blockers or nitrates. The ejection
fraction was higher and regional wall-motion score lower
during both low-dose and high-dose dobutamine in patients
with contractile reserve in $5 segments (Table 2). The
influence of contractile reserve on subsequent survival dur-
ing medical therapy is shown in Figure 1. Initial survival in
patients with contractile reserve in $5 myocardial segments
was significantly greater than those with contractile reserve
in fewer segments.
In addition to improved survival, patients with contractile
reserve in $5 segments were in lower NYHA functional
class at the last follow-up contact than were patients with
contractile reserve in ,5 segments (2.4 6 1.3 vs. 3.2 6 1.1;
p , 0.02). The Canadian Cardiovascular Society anginal
class in patients who were alive at the last follow-up was
similar in the 22 patients with contractile reserve in $5
segments and the 6 patients with contractile reserve in ,5
segments (1.3 6 0.8 vs. 1.2 6 0.4). Four patients (8%)
developed a nonfatal myocardial infarction during the
follow-up period. The presence and the extent of contractile
reserve and ischemic responses were not predictive of
nonfatal myocardial infarction.
Although patients with contractile reserve in $5 seg-
ments had significantly better survival during the first one to
two years than did patients with less evidence of myocardial
viability, this initial survival advantage was not maintained
beyond the second year. Survival in patients with contractile
reserve in $5 segments declined thereafter, resulting in
survival rates at three years of medical therapy that were
equivalent between the two groups (Fig. 1).
Outcome with medical therapy compared to myocardial
revascularization. Among the 58 patients with evidence of
contractile reserve in $5 dysfunctional segments, there was
no difference in the number of viable segments between the
24 patients who underwent revascularization (10.1 6 3.0
segments/patient) compared to the 34 patients who were
treated medically (9.3 6 2.8 segments/patient). These
groups did not differ with respect to age, NYHA functional
class, previous myocardial infarction, or revascularization.
The ejection fraction and regional wall-motion score also
did not differ between these two groups at baseline or during
low-dose and high-dose dobutamine. However, patients
who underwent revascularization demonstrated a greater
number of ischemic segments during DSE than did patients
Table 1. Univariate Predictors of Cardiac Mortality in Medically Treated Patients
Predictor
Relative Risk
p
ValueMean 95% CI
Age (yr) 0.970 0.938, 1.002 0.074
NYHA functional class 1.809 1.082, 3.027 0.028
Drug therapy—ACE inhibitors 1.185 0.471, 2.981 0.721
Beta-blockers 0.850 0.281, 2.568 0.770
Calcium channel blockers 0.851 0.284, 2.550 0.773
Nitrates 1.562 0.516, 4.725 0.433
Dobutamine—peak dose 0.952 0.907, 0.998 0.046
Regional wall-motion score—baseline 1.349 0.464, 4.000 0.612
Low-dose dobutamine 2.355 0.903, 6.138 0.086
Peak-dose dobutamine 2.074 0.935, 4.600 0.079
Ejection fraction—baseline 0.943 0.876, 1.014 0.119
Low-dose dobutamine 0.941 0.889, 0.996 0.039
Peak-dose dobutamine 0.945 0.896, 0.997 0.045
No. segments with ischemia only 1.266 1.054, 1.521 0.015
No. segments with CR 0.856 0.761, 0.962 0.011
No. segments with CR only 0.875 0.768, 0.997 0.050
No. segments with CR and ischemia 0.842 0.640, 1.110 0.228
No. segments with CR or ischemia 0.898 0.795, 1.009 0.077
No. segments with fixed abnormality 1.119 0.996, 1.256 0.063
Analysis by Cox proportional hazards model.
ACE 5 angiotensin-converting enzyme; CR 5 contractile reserve; NYHA 5 New York Heart Association.
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treated medically (4.7 6 3.1 vs. 2.7 6 2.8 segments/patient,
respectively; p , 0.02). In the patients with $5 segments
manifesting contractile reserve, survival was significantly
better in patients who underwent revascularization (93 6
6% at 3 years) compared to those who were treated
medically (49 6 15%, p , 0.02) as shown in Figure 2. In
addition, 63% of revascularized patients were asymptomatic
at the last follow-up contact compared to 32% of those
treated medically (p , 0.03).
In the 22 patients with either no evidence of contractile
reserve in dysfunctional segments or with only 4 or fewer
segments with contractile reserve, 4 patients (18%) under-
went myocardial revascularization (all with coronary artery
bypass surgery). All four of these patients died, and three
died within one month of revascularization, as shown in
Figure 3. Survival was significantly greater in the 18 patients
who were managed medically compared to the 4 patients
who underwent myocardial revascularization (p , 0.007).
Table 2. Patient Characteristics
Medical Therapy
No. Segments with CR
Revascularization
No. Segments with CR
p Value>5 <5 >5 <5
No. of patients 34 18 24 4
Male 29 (85%) 12 (67%) 19 (79%) 4 (100%) , 0.31
Age (yr) 65 6 12 65 6 11 64 6 13 67 6 3 , 0.97
History of MI 26 (76%) 14 (78%) 15 (63%) 3 (75%) , 0.63
Previous PTCA 7 (21%) 0 (0%) 5 (21%) 0 (0%) , 0.15
Previous CABG 11 (32%) 6 (33%) 4 (17%) 2 (50%) , 0.40
NYHA functional class 2.9 6 1.2 3.0 6 1.0 2.5 6 1.1 2.9 6 1.2 , 0.45
CAD (no. of vessels $50%) 2.0 6 0.8 2.4 6 0.7 2.5 6 0.6 2.8 6 0.5 , 0.07
Heart rate—baseline 76 6 13 85 6 16 82 6 14 79 6 8 , 0.15
Low-dose dobutamine 80 6 17 90 6 18 89 6 15 85 6 8 , 0.16
Peak-dose dobutamine 117 6 21 122 6 17 120 6 20 102 6 4 , 0.28
Regional wall-motion score—baseline 3.2 6 0.4 3.2 6 0.5 3.1 6 0.5 3.2 6 0.2 , 0.62
Low-dose dobutamine 2.8 6 0.5 3.2 6 0.5* 2.5 6 0.6 3.2 6 0.1* , 0.005
Peak-dose dobutamine 2.7 6 0.6 3.4 6 0.5* 2.6 6 0.7 3.4 6 0.2* , 0.005
Ejection fraction—baseline (%) 28 6 7 24 6 7 27 6 7 24 6 4 , 0.28
Low-dose dobutamine (%) 35 6 9 27 6 11* 34 6 7 28 6 3 , 0.009
Peak-dose dobutamine (%) 39 6 10 30 6 8* 38 6 9 28 6 5 , 0.006
No. segments with contractile reserve 9.3 6 2.8 1.2 6 1.2 10.0 6 3.0 1.5 6 1.7 —
No. segments with ischemia 2.7 6 2.8 2.8 6 2.8 4.7 6 3.1 3.8 6 3.6 , 0.09
*p , 0.05 vs. $5 segments with contractile reserve.
CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery disease; CR 5 contractile reserve; MI 5 myocardial infarction; NYHA 5 New York Heart
Association; PTCA 5 percutaneous transluminal coronary angioplasty.
Figure 1. Survival in 52 patients treated medically. Patients are
subdivided into 34 patients with substantial myocardial viability in
dysfunctional segments, defined as contractile reserve during do-
butamine echocardiography in $5 myocardial segments, and 18
patients with evidence of minimal or no contractile reserve.
Figure 2. Survival in 58 patients with contractile reserve in $5
myocardial segments with systolic dysfunction under basal condi-
tions. Patients are subdivided into 24 patients treated with myo-
cardial revascularization and 34 patients treated medically.
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DISCUSSION
In patients with CAD, LV function is among the most
important determinants of both short-term and long-term
prognosis (1–5). It has become apparent recently that
resting LV dysfunction does not always represent an irre-
versible process, as LV function may improve and even
normalize after myocardial revascularization in a subset of
patients (6–11). Moreover, data from recent studies suggest
that the improvement in LV function after revascularization
is associated with reduced heart failure symptoms (13,42)
and enhanced long-term survival (12–14). However, pa-
tients with LV dysfunction undergo coronary artery bypass
surgery or coronary angioplasty with an increased risk of
procedure-related death, and not all patients manifest an
improvement in LV function despite successful myocardial
revascularization. Hence, the distinction between dysfunc-
tional myocardium that is viable from that which is nonvi-
able has important implications regarding the selection of
patients in whom these risks associated with revasculariza-
tion are justified. The current study indicates that assess-
ment of the degree of myocardial viability, as assessed by
myocardial contractile reserve, also has important prognos-
tic implications.
Assessment of myocardial viability. Several noninvasive
imaging techniques have evolved during the past decade for
assessing myocardial viability (43). These include PET for
evaluating myocardial perfusion and metabolism (12–
14,44,45); thallium-201 or technetium-99m sestamibi per-
fusion imaging for evaluating myocardial perfusion and cell
membrane integrity (18,46–50); and low-dose DSE for
evaluating myocardial contractile reserve (15–35). Each of
these methods has been used in several studies to predict
which myocardial regions with contractile dysfunction will
improve after revascularization, with excellent positive and
negative predictive accuracies (51,52), but the relative diag-
nostic potential of these techniques has not been fully
defined. The number of patients studied thus far by either of
these methods is small, and the number of studies in which
the relative diagnostic accuracies of these methods have
been compared in the same cohort of patients undergoing
revascularization is even more limited (18,24,25,27,28,30–
32,48).
Myocardial viability and clinical outcome. These com-
parative diagnostic issues are clinically relevant only if both
the presence and the extent of viable myocardium in
patients with chronic LV dysfunction are related to subse-
quent outcome and if the identification of myocardial
viability translates into management strategies that improve
outcome. Our data using low-dose DSE support these
concepts. Both the presence and the extent of contractile
reserve in myocardial segments with resting contractile
dysfunction were strong determinants of survival during
medical therapy; the same was true for the presence and
extent of inducible myocardial ischemia.
Our findings also indicate a significant improvement in
survival with revascularization compared with medical ther-
apy in patients with viable but dysfunctional myocardium.
Survival in patients with contractile reserve in five or more
segments was significantly greater in those who underwent
revascularization compared with patients treated medically
(Fig. 2). These data suggest that patients with substantial
myocardial viability despite LV dysfunction are a group in
whom survival may be enhanced with myocardial revascu-
larization. The results of the current study are consistent
with three recent studies using PET in which patients with
evidence of viable but dysfunctional myocardium who un-
derwent revascularization had better survival than did those
who were treated medically (12–14).
Our results in patients treated medically, however, differ
from several previous studies. Our finding of initial greater
survival in patients with contractile reserve contrasts with
two PET studies demonstrating worse survival during
medical therapy in patients with myocardial viability (de-
fined as preserved metabolic activity in regions of underper-
fused myocardium) than in patients without evidence of
myocardial viability (12–13); these PET studies are sup-
ported by a third study using DSE (53). However, our
results in medically treated patients are very similar to
observations made two decades ago in a small number of
patients in whom contractile reserve was evaluated using
epinephrine infusion or postextrasystolic potentiation dur-
ing left ventriculography, in whom the presence of viable
myocardium manifesting contractile reserve was associated
with enhanced long-term survival during medical therapy
(54). Moreover, in a third PET study of patients with LV
dysfunction (14) survival rates during medical therapy in
patients with viable myocardium were not greater than in
those with no evidence of viable myocardium (86% vs. 87%
at 1.5 years), results comparable to the present study.
The apparent differences in the survival results during
medical therapy that have been observed in patients with
Figure 3. Survival in 22 patients with contractile reserve in ,5
dysfunctional myocardial segments. Patients are subdivided into 4
patients treated with myocardial revascularization and 18 patients
treated medically.
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viable myocardium in the setting of LV dysfunction (12–
14,53,54) can be reconciled by the finding that the initial
favorable survival trend in patients with contractile reserve
in our series was not maintained over the course of two to
three years (Fig. 1), suggesting that any survival advantage
in patients with myocardial viability seems to be short-lived
and time-dependent. Thus, the apparent discrepancies in
survival among patients with LV dysfunction and viable
myocardium reported in previous studies may be related to
different time points along this continuum in which the
patients were enrolled. This observation also supports the
growing awareness that dysfunctional but viable myocar-
dium represents jeopardized myocardium in which viability
may not be maintained indefinitely (55,56).
Study limitations. Our data were obtained in patients in
whom treatment decisions were not randomly assigned, and
in some cases management strategies were based, in part, on
the results of DSE. This represents an important limitation
of our study. This limitation is also present in previous
studies assessing the effect of medical therapy and revascu-
larization in patients with viable myocardium assessed by
PET (12–14), thallium imaging (57) and contrast left
ventriculography (54). The lack of randomization could
introduce potential biases into our results and contribute to
the observed differences in outcome. However, there were
no significant differences in age, symptoms, resting LV
dysfunction or severity of CAD on coronary angiography
between patients with and those without contractile reserve,
or between patients with contractile reserve treated medi-
cally and those treated with myocardial revascularization
(Table 2). The patients undergoing revascularization did
have a greater extent of inducible myocardial ischemia (as
assessed by DSE), which undoubtedly could have contrib-
uted to the decision in favor of revascularization in some
patients, but this alone would not contribute to the better
outcome observed in the revascularized patients, because
patients with LV dysfunction and inducible ischemia would
be expected to have a worse prognosis and a higher mortality
than would those without ischemia (58,59). Thus, the
greater extent of ischemic myocardium in the revasculariza-
tion group did not bias that group toward better survival
than the group treated medically.
Most patients had evidence of contractile reserve; 89%
had contractile reserve in at least one segment, 78% in $3
segments and 73% in $5 segments. This prevalence is
greater than in most previous investigations. In addition,
our results were obtained in a relatively small number of
patients in each subgroup and thus must be considered
tentative until confirmed by other larger series.
Conclusions. Despite these limitations, our data indicate
that LV contractile reserve and myocardial viability, as
assessed by low-dose DSE, significantly influence prognosis
in patients with CAD and chronic LV dysfunction. Al-
though patients with contractile reserve may have an initial
survival advantage compared to those with no evidence of
viability, this advantage is temporary and is lost over the
course of two years. In contrast, patients with contractile
reserve who undergo myocardial revascularization have an
excellent outcome. Hence, DSE may identify a subset of
patients with impaired LV function who are candidates
either for coronary artery bypass surgery or angioplasty.
These data support the concepts that both the presence and
the extent of viable myocardium are important determinants
of prognosis in patients with CAD and LV dysfunction and
that both survival and symptomatic status are enhanced by
revascularization in patients with systolic dysfunction who
manifest myocardial contractile reserve. These concepts
warrant testing in larger-scale prospective randomized trials.
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